Summary of use during lactation
Topical ingenol mebutate has not been studied during breastfeeding. However, after topical administration, serum concentrations were undetectable, so breastfeeding is not expected to result in exposure of the breastfed infant. If ingenol mebutate is required by the mother, it is not a reason to discontinue breastfeeding. Do not apply ingenol mebutate to the breast or nipple and ensure that the infant's skin does not come into direct contact with the areas of skin that have been treated.
Drug levels in milk and infant serum
Maternal Levels. According to the manufacturer, serum concentrations of ingenol mebutate and its two metabolites are below the limit of detection (<0.1 mcg/L) after topical application of approximately 1 gram of 0.05% gel to an area of 100 sq. cm. Infant Levels. Relevant published information was not found as of the revision date.
Effects in breastfed infants
Relevant published information was not found as of the revision date.
Effects on lactation and breastmilk
Relevant published information was not found as of the revision date.
Source: Drugs and Lactation Database (LactMed®), National Institute of Child Health and Human Development, NCBI Bookshelf. Check LactMed for the most recent revision.
Medical disclaimer: This page is for qualified healthcare professionals and is a decision-support aid only. It does not replace clinical judgement, local protocols or product information. Verify every dose and threshold before use. See the full Medical Disclaimer.